Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HT-100 Long-term Safety in DMD
NCT02525302Phase 2Terminated
- Sponsor
- Akashi Therapeutics
- Start
- May 2015
- Primary completion
- Dec 2016
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of halofuginone in Duchenne muscular dystrophy (DMD), sponsored by Akashi Therapeutics. Started May 2015; status: terminated.
02
Drugs
halofuginone
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT02525302.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02525302.